Toward Preventing Transplant Rejection with Immunologically Matched Stem Cells

Matching the immunological characteristics of donor retinal cells to those of the recipient can reduce the chance of rejection.

Written byRuth Williams
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

FLICKR, RUTH HARTNUPDonor stem cell–derived retinal epithelial cells whose immune proteins correspond to those of a recipient are tolerated following transplant into monkeys’ eyes, according to a report published today (September 15) in Stem Cell Reports. In an accompanying paper, the team also reports that such immune-matched retinal cells derived from humans prevent immune responses in cultured human lymphocytes.

“These are extremely important studies that provide an attractive solution to one of the main problems in regenerative medicine. They show that cells derived from HLA [human leukocyte antigen]-matched homozygous donors could be used to treat patients without the need for powerful immunosuppressive drugs, which of course are associated with cancer, infections, and a long list of other side effects,” said stem cell researcher Robert Lanza of the Astellas Institute for Regenerative Medicine in Marlborough, Massachusetts, who was not involved in the work.

The major histocompatibility complex (MHC)—or, as it’s called in humans, the human leukocyte antigen (HLA) system—is a family of proteins differentially expressed on the surface of cells that enables the body’s immune system to distinguish self from non-self and react accordingly. Indeed, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • ruth williams

    Ruth is a freelance journalist. Before freelancing, Ruth was a news editor for the Journal of Cell Biology in New York and an assistant editor for Nature Reviews Neuroscience in London. Prior to that, she was a bona fide pipette-wielding, test tube–shaking, lab coat–shirking research scientist. She has a PhD in genetics from King’s College London, and was a postdoc in stem cell biology at Imperial College London. Today she lives and writes in Connecticut.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies